Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants

Pharmacy World and Science

Volumn 20, Issue 3, 1998, Pages 123-130

  Zielinska E ^a,b   Niewiarowski, W ^c   Bodalski, J ^b   Rebowski G ^c   Skretkowicz J ^b   Mianowska, K ^b   Sekulska, M ^b  

^a Med Univ of Lódź ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

Acetylation; Hypersensitivity; Infants; NAT2 genotype; Trimethoprim sulfamethoxazole

Indexed keywords

ACYLTRANSFERASE; COTRIMOXAZOLE; ISONIAZID;

ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; DRUG ACETYLATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GRANULOCYTOPENIA; HUMAN; INFANT; INFECTION; PHENOTYPE; POLYMERASE CHAIN REACTION; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLATION; ALLELES; ANTI-INFECTIVE AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG HYPERSENSITIVITY; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; PNEUMONIA, PNEUMOCYSTIS; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0031924220     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008664707825     Document Type: Article

References (38)

1. Davey RTJ, Masur H. Recent advances in the diagnosis, treatment and prevention of Pneumocystis carini pneumonia. Antimicrob Agents Chemother 1990;34:499-504.
2. Goodwin SD. Pneumocystis carini pneumonia in human immunodeficiency virus-infected infants and children. Pharmacotherapy 1993;13:640-6.
3. Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium dependent epitopes on the glycoprotein IIb/IIIa complex. Blood,1994;84:176-83.
4. Gupta A, Eggo MC, Uetrecht JP, Cribb AE, Daneman D, Rieder MJ, Shear NH, Cannon M, Spielberg SP. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992;51:56-67.
5. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994;6:1017-24.
6. Murphy JL. Renal tubular acidosis in children treated with Trimethoprim-Sulfamethoxazole during therapy for acute lymphoid leukemia. Pediatrics 1992;89:1072-4.
7. Rieder MJ, Sisson E, Bird IA, Almawi WY. Suppression of T-lymphocyte proliferation by sulphonamide hydroxylamines. Int J Immunopharmac 1992; 14:1175-80.
8. Uetrecht JP, Shear NH, Zahid N. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system. Drug Metab Dispos 1993;21:830-834.
9. Carr A, Tindall B, Penny R, Cooper DA. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993;94:21-5.
10. Cribb AE, Spielberg SP Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992;51:522-6.
11. Lee BL, Delahunty T, Safrin S. The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1994;56: 184-9.
12. Van der Ven AJAM, Mantel MA, Vree TB, Koopmans PP, van der Meer JW. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br J Clin Pharmacol 1994;38:147-50.
13. Van der Ven AJAM, Vree TB, Koopmans PP, van der Meer JWMN. Metabolites and side effects of trimethoprim-sulfonamide combinations. Chemotherapie J 1997;6:28-30.
14. 1-glucuronide conjugates in healthy human volunteers. Clin Drug Invest 1995;9:43-53.
15. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetyltransferase in determining sulfamethoxazole metabolism. Biochemical Pharmacology 1993;45:1277-82.
16. Nakamura H, Uetrecht J, Cribb AE, Miller MA, Zahid N, Hill J, Josephy PD, Grant DM, Spielberg SP. In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. J Pharmacol Exp Ther 1995;274:1099-104.
17. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-7.
18. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1994;8:333-7.
19. Agúndez JAG, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994; 56:202-9
20. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57: 581-92.
21. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992; 267: 18140-47.
22. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiach SJ, McCarthy A, Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297: 441-5.
23. Bell DA, Taylor AJ, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogensis 1993;14:1689-92.
24. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogenes in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
25. 341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab Disp 1994;22:371-6.
26. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
27. Hickman D, Risch A, Camilleri J, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992;2:217-26.
28. Grant DM. Molecular genetics of the N-acetyltransferase. Pharmacogenetics 1993;3:45-50.
29. Vesell ES. The model drug approach in clinical pharmacology. Clin Pharmacol Ther 1991;50:239-48.
30. Skrȩtkowicz J, Zasada M, Polakowski P. Porównanie dwóch najczȩściej stosowanych metod oznaczania fenotypu acetylacji. Farmacja Polska 1990; 46:149-51.
31. Vatsis KP, Weber WW, Bell DA, Dupert JM, Evans DAP, Grant DM, Hein DW, et al. Nomenclature for N-acetyltransferases. Pharmaogenetics 1995;5:1-17.
32. Rane A. The major physiological factors that modulate drug metabolism in man. Implications for drug effects and toxicity. In: Pacifici GM, Fracchia GN, eds. Advances in drug metabolism in man. Brussels, Luxembourg: ECSC-EC-EAEC, 1995.
33. Mashomo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetyltransferase polymorphism to predict phenotype. Hum Genet 1992; 90:139-43.
34. Pariente-Khayat A, Rons G, Rey E, Richard MO, D'athis Ph, Moran C, Badoual J, Olive G. Caffeine acetylator phenotyping during maturation in infants. Pediatric Reseach 1991;29:492-5.
35. Zielińska E, Niewiarowski W, Bodalski J, Rȩbowski G, Skrȩtkowicz J, Polakowski P. Relation between genotype for human arylamine N-acetyltransferase (NAT2) and phenotype acetylation in children under 2 years old. Thérapie 1995;suppl:84 (abstract).
36. Zielińska E, Niewiarowski W, Bodalski J, Rȩbowski G, Matusiak I. Molecular genotyping of the arylamine N-acetyltransferase polymorphism in children. Medical Science Monitor 1997; in press.
37. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996; 59: 376-82.
38. Blaser J, Joos B, Opravil M, Lüthy R. Variability of serum concentration of Trimethoprim and Sulfamethoxazole during high dose therapy. Infection 1993;21:206-9.